A widely prescribed class of blood pressure medications may carry unexpected risks for people managing type 2 diabetes and kidney disease.
According to research presented by the European Renal Association, patients taking dihydropyridine calcium-channel blockers (DCCBs) faced a 33% higher risk of major kidney complications than those on other blood pressure treatments.
Key Highlights
- The Study: Researchers tracked over 31,000 adults with type 2 diabetes over 3.5 years. All participants were already taking standard, kidney-protective medications (RAS and SGLT2 inhibitors).
- The Risk: Nearly 40% of patients were also taking a DCCB. These patients were significantly more likely to experience a 40%+ drop in kidney function or progress to end-stage kidney disease requiring dialysis or a transplant.
- The Mechanism: DCCBs lower blood pressure by relaxing blood vessels. However, they may dilate the vessels supplying blood to the kidney filters more than those carrying blood away, unintentionally increasing internal pressure and damaging the organs over time.
What It Means for Patients
Because this was an observational study, it proves an association rather than direct causation, and further clinical trials are needed. However, researchers caution that these common drugs may not always be the safest second-line choice for diabetic kidney disease.
Patients taking blood pressure medication should consult their doctor before altering their prescription.
Source: Science Daily
